// App-Quantinova.ai

LBA4 : Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Researchers

Presenter

  • Antonio Palumbo

Principal Investigators

  • Katja Weisel

  • Ajay K. Nooka

  • Tamas Masszi

  • Meral Beksac

  • Ivan Spicka

  • Vania T.M. Hungria

  • Markus Munder

  • Maria-Victoria Mateos

  • Tomer Martin Mark

  • Ming Qi

  • Jordan Mark Schecter

  • Himal Amin

  • Xiang Qin

  • William Deraedt

  • Tahamtan Ahmadi

  • Andrew Spencer

  • Pieter Sonneveld

Medical Centers

  • University of Turin, Turin, Italy

  • Mayo Clinic, Jacksonville, FL

  • Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Tubingen, Germany

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • Fovarosi Onkormanyzat Szent Laszlo Korhaza, Hematologia, Budapest, Hungary

  • Ankara Universitesi Tip Fakultesi, Ankara, Turkey

  • Vseobecna Fakultni Nemocnice V Praze, Prague, Czech Republic

  • Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Brazil

  • University Medical Center of the Johannes Gutenberg-University, Third Department of Medicine, Mainz, Germany

  • University Hospital of Salamanca, Salamanca, Spain

  • New York Presbyterian Weill CornellA Hospital, New York, NY

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, LLC, Raritan, NJ

  • Johnson and Johnson, Philadelphia, PA

  • The Alfred Hospital, Melbourne, Australia

  • Erasmus University Medical Center, Rotterdam, Netherlands

Locations

  • Brazil

  • Czech Republic

  • Italy

  • Netherlands

  • Germany

  • Turkey

  • Spain

  • Australia

  • United States

  • Hungary

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

Outcome

  • Unknown

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT02136134

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved